These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8042911)

  • 41. Study on the existence of TRH in the cerebrospinal fluid in humans.
    Ishikawa H
    Biochem Biophys Res Commun; 1973 Oct; 54(3):1203-9. PubMed ID: 4201809
    [No Abstract]   [Full Text] [Related]  

  • 42. Abnormal anterior pituitary responsiveness to hypothalamic hormones in primary affective disorders. Effect of desipramine therapy.
    Brambilla F; Scarone S; Massironi R; Nobile P; Pugnetti L
    Neuropsychobiology; 1982; 8(5):269-75. PubMed ID: 6813760
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuropeptides in the cerebrospinal fluid (CSF) in psychiatric disorders.
    Rafaelsen OJ; Gjerris A
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):533-8. PubMed ID: 3937176
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CSF magnesium in affective disorder: lack of correlation with clinical course of treatment.
    George MS; Rosenstein D; Rubinow DR; Kling MA; Post RM
    Psychiatry Res; 1994 Feb; 51(2):139-46. PubMed ID: 8022948
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is there any relationship between anticonvulsant and mood-stabilizing effects of carbamazepine?
    Motohashi N; Kubota M; Onose H; Kariya T
    Pharmacopsychiatry; 1994 Jul; 27(4):176. PubMed ID: 7972350
    [No Abstract]   [Full Text] [Related]  

  • 46. Pituitary-thyroid responsiveness to intramuscular thyrotropin-releasing hormone based on analyses of serum thyroxine, tri-iodothyronine and thyrotropin concentrations.
    Azizi F; Vagenakis AG; Portnay GI; Rapoport B; Ingbar SH; Braverman LE
    N Engl J Med; 1975 Feb; 292(6):273-7. PubMed ID: 803298
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of antenatal thyrotropin-releasing hormone on uterine contractility, blood pressure, and maternal heart rate.
    Devlieger R; Vanderlinden S; de Zegher F; Van Assche FA; Spitz B
    Am J Obstet Gynecol; 1997 Aug; 177(2):431-3. PubMed ID: 9290464
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of carbamazepine on pituitary-adrenal function in healthy volunteers.
    Perini GI; Devinsky O; Hauser P; Gallucci WT; Theodore WH; Chrousos GP; Gold PW; Kling MA
    J Clin Endocrinol Metab; 1992 Feb; 74(2):406-12. PubMed ID: 1309836
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thyrotropin-releasing hormone metabolism is attenuated in the cerebrospinal fluid of the human neonate.
    Rao JK; Ponte E; Lopez A; Jayaraman A; Prasad C
    Neuropeptides; 1986; 8(2):159-63. PubMed ID: 3093912
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The inhibition by somatostatin of the thyrotropin response to thyrotropin-releasing hormone in normal subjects.
    Weeke J; Hansen AP; Lundbaek K
    Scand J Clin Lab Invest; 1974 Apr; 33(2):101-3. PubMed ID: 4212424
    [No Abstract]   [Full Text] [Related]  

  • 51. Amyotrophic lateral sclerosis: thyrotropin-releasing hormone and histidyl proline diketopiperazine in the spinal cord and cerebrospinal fluid.
    Jackson IM; Adelman LS; Munsat TL; Forte S; Lechan RM
    Neurology; 1986 Sep; 36(9):1218-23. PubMed ID: 3092130
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Investigation of cerebrospinal fluid neuropeptides in idiopathic senile dementia.
    Oram JJ; Edwardson J; Millard PH
    Gerontology; 1981; 27(4):216-23. PubMed ID: 6116646
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Response of thyrotropin to thyrotropin-releasing hormone as predictor of treatment outcome. Prediction of recovery and relapse in treatment with antidepressants and neuroleptics.
    Langer G; Koinig G; Hatzinger R; Schönbeck G; Resch F; Aschauer H; Keshavan MS; Sieghart W
    Arch Gen Psychiatry; 1986 Sep; 43(9):861-8. PubMed ID: 2875702
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of antidepressant medication on morning and evening thyroid function tests during a major depressive episode.
    Duval F; Mokrani MC; Crocq MA; Jautz M; Bailey P; Diep TS; Macher JP
    Arch Gen Psychiatry; 1996 Sep; 53(9):833-40. PubMed ID: 8792760
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thyrotropin and prolactin responses to different doses of thyrotropin-releasing hormone in depression.
    Masturzo P; Tosca P; Murialdo G; Somenzini G; Cairoli S; Filippi U; De Palma D; Balbi D; Zerbi F
    Neuropsychobiology; 1989; 20(3):120-5. PubMed ID: 2503767
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of melancholia during carbamazepine treatment in borderline personality disorder.
    Gardner DL; Cowdry RW
    J Clin Psychopharmacol; 1986 Aug; 6(4):236-9. PubMed ID: 3525615
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thyrotropin-releasing hormone immunoreactivity in human blood, urine, spinal fluid, amniotic fluid, saliva, and gastric juice.
    Suhonen-Malm AS
    Acta Endocrinol (Copenh); 1987 Apr; 114(4):552-8. PubMed ID: 3107296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thyrotrophin response to thyreostimulin in affectively ill women relationship to suicidal behaviour.
    Linkowski P; Van Wettere JP; Kerkhofs M; Brauman H; Mendlewicz J
    Br J Psychiatry; 1983 Oct; 143():401-5. PubMed ID: 6414565
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression.
    Ketter TA; Post RM; Parekh PI; Worthington K
    J Clin Psychiatry; 1995 Oct; 56(10):471-5. PubMed ID: 7559374
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effects of carbamazepine on resting metabolic rate and thyroid function in depressed patients.
    Herman R; Obarzanek E; Mikalauskas KM; Post RM; Jimerson DC
    Biol Psychiatry; 1991 Apr; 29(8):779-88. PubMed ID: 2054452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.